Posted by Michael Wonder on 11 Aug 2021
Swing Therapeutics receives FDA breakthrough device designation for digital therapeutic for the management of fibromyalgia, launches real world study
11 August 2021 - Approach based on acceptance and commitment therapy and a foundational clinically validated digital program licensed from University of Manitoba.
Swing Therapeutics announced today that the U.S. FDA has granted breakthrough device designation to the company’s digital therapeutic for the management of fibromyalgia.
